In the present study, 21% of the patients had copeptin elevations before treatment and copeptin elevations were mainly seen in patients without myocardial ischemia and without elevations in cTnI, questioning its relation to cardiotoxicity. Here, TNNI3 is linked to myocardial ischemia.